The combination of IL10 and XCL1 could stimulate or activate NK cells and cytotoxic T cells, which could promote the production of tumor necrosis factor alpha (TNFα) and inhibit the production of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP2), thereby achieving an anti‐cancer therapeutic effect. The gene discussed is MMP2; the disease is cancer.